Boston Scientific Acquires Penumbra to Expand its Vascular Health Portfolio
- 3 days ago
- 2 min read
In a massive move to dominate the vascular health market, Boston Scientific announced on Thursday, January 15, 2026, a definitive agreement to acquire Penumbra for approximately $14.5 billion. This strategic acquisition, one of the first major medtech deals of the year, allows Boston Scientific to secure a leading position in the high-growth segments of thrombectomy and embolization.
The deal values Penumbra at $374 per share, representing a 19% premium over its recent trading price. Shareholders may elect to receive payment in cash or Boston Scientific stock, with the total consideration structured as approximately 73% cash and 27% stock. To finance the $11 billion cash portion, Boston Scientific will utilize a combination of cash on hand and new debt.
Penumbra is a specialist in devices designed to remove blood clots from blood vessels and systems to control bleeding. These technologies are critical for treating conditions such as pulmonary embolism, stroke, and deep vein thrombosis. Boston Scientific CEO Mike Mahoney noted that the purchase offers a unique "opportunity to enter new, fast-growing segments within the vascular space".
The acquisition follows a busy week for Boston Scientific, which recently announced the buyout of urology medtech Valencia Technologies. Analysts view Penumbra as a "growth asset," noting its preliminary 2025 revenue of $1.4 billion, a 17% increase year-over-year.
Following the news, Penumbra’s stock surged nearly 10% pre-market, while Boston Scientific’s shares saw a slight decline of approximately 4% to 5%. The transaction is expected to be slightly dilutive to adjusted earnings per share in the first year but is projected to become accretive thereafter.
Upon the deal's expected close in 2026, Penumbra’s Chairman and CEO, Adam Elsesser, will join the Boston Scientific board of directors. The merger remains subject to shareholder approval and customary closing conditions.
🔖 Sources
Keywords: Boston Scientific acquires Penumbra
Boston Scientific acquires Penumbra
Comments